ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Strategy and Utility of Checkpoint Inhibitor Therapy in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation

L. Jeng, S. Hsu, A. Thorat

China Medical University Hospital, Taichung, Taiwan

Meeting: 2020 American Transplant Congress

Abstract number: A-153

Keywords: Liver transplantation, Malignancy

Session Information

Session Name: Poster Session A: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Checkpoint inhibitor therapy is a hot and rapidly progressive therapy in advanced cancer patients in the past 2 years. Although some successful case report published about check-point therapy after organ transplantation, it is still contra-indicated to OLT patient because of the possibility of rejection.

*Methods: Until October 31st, 2019, 11 HCC patients receiving checkpoint inhibitor therapy for hepatocellular carcinoma recurrence or metastasis after liver transplantation (Table 1). 4 patients receive Pembrolizumab, 5 patients receive Nivolumab, 1 patient receives Pembrolizumab initially and switches to Nivolumab and another 1 patient is contrary. Besides, 3 patients receive target therapy, 2 patients receive dendritic cell therapy and 2 patients receive target therapy and dendritic therapy as well. The immunosuppression strategy for these patients is higher steroid dosage and lower CNI dosage.

*Results: Survival days are 1 month to 19 months and administration times are 1 to 21 times. 4 patients with partial responses are approved and 4 patients with progression are approved as well. There are 2 patients alive until now. Both of these 2 patients receive combined therapy of check-point inhibitor, target therapy, and dendritic therapy. Only 1 patient has approved liver graft rejection and dead of liver failure.

*Conclusions: Check-point inhibitor therapy could be a feasible and effective treatment in HCC recurrence or metastasis after LT, but we need more experiences to adjust immunosuppression. In our experiences, multidisciplinary treatment is better than single using of checkpoint inhibitor. It is similar to the results of clinical trials in advanced HCC.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Jeng L, Hsu S, Thorat A. The Strategy and Utility of Checkpoint Inhibitor Therapy in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-strategy-and-utility-of-checkpoint-inhibitor-therapy-in-patient-with-hepatocellular-carcinoma-recurrence-following-liver-transplantation/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences